Prognostic impact of next-generation sequencing on myelodysplastic syndrome: A single-center experience
Hale Bülbül,Özge Özer Kaya,Fatma Keklik Karadağ,Aybüke Olgun,Zühal Demirci,Cengiz Ceylan
DOI: https://doi.org/10.1097/md.0000000000039909
IF: 1.6
2024-10-15
Medicine
Abstract:A diverse collection of myeloid disorders known as myelodysplastic syndromes (MDS) arise from progenitor or stem cells and contributed to the existence of clonal hematopoiesis. Numerous mutations in genes of stem cell during MDS development affect their proliferation and differentiation. This leads to a build-up of aberrant, immature myeloid cells in blood and marrow, which disrupts normal hematopoiesis. [ 1–3 ] Although RBP4, AHSG, and LRG are the most promising MDS marker candidates the widespread heterogeneity in MDS has also been demonstrated in proteomic case studies of MDS in progression. [ 4 ] One of the characteristics of MDS was a higher probability of acute myeloid leukemia (AML) transformation. According to the World Health Organization's (WHO) 5th edition classification (WHO 2022), the myeloblast threshold requires ≥20% in both peripheral blood or bone marrow for AML. The International Consensus Classification and WHO 2022 differ in terms of blast threshold. Ten percent or more blasts in the peripheral blood or bone marrow are required by the International Consensus Classification. [ 5 ] About 30% to 40% of patients with MDS have transformation to AML, which is known as "secondary AML to MDS" and is connected to a minimum of 20% myeloblast count. [ 6 , 7 ] Nonetheless, a majority of individuals with myelodysplastic syndromes possess a normal karyotype, and individuals with similar chromosomal abnormalities frequently exhibit different clinical presentations. Recent advancements in next-generation sequencing (NGS) have made it achievable to locate novel genetic abnormalities. A growing variety of genetic abnormalities have been linked to myeloid neoplasm development, progression, and prognosis. [ 8–10 ] Recurrent somatic mutations over a number of genes were found at the time of diagnosis and during leukemic transformation in MDS patients by the use of sequencing techniques. The molecules involved in DNA methylation, chromatin modification, RNA splicing, transcription, signal transduction, cohesin regulation, and DNA repair are among the main targets of mutations in MDS. Genes implicated in chromatin modification (EZH2, ASXL1), DNA methylation (DNMT3A, TET2, and IDH1–2), transcriptional regulation (RUNX1, GATA2, and EVI1), a cohesin complex, and RNA splicing (SF3B1, SRSF2, U2AF1, and ZRSR2) were found to be recurrently mutated. [ 2 , 11–13 ] SF3B1, ASXL1, DNMT3A, SRSF2, RUNX1, TET2, EZH2, U2AF1, IDH1/2, TP53, ETV6, SETBP1, JAK2, CBL, STAG2, ZRSR2, and NRAS were the most often altered genes, while no mutant genes were detected in more than one-third of cases. Adverse clinical aspects, including poor/very poor cytogenetics such as complex karyotypes (TP53), thrombocytopenia (NRAS, RUNX1, and TP53) and enhanced blast proportion (NRAS, RUNX1, and TP53) are linked to several of these gene variants. Despite numerous gene mutations have value for predicting survival and are associated with poor clinical features, they are not included in prognostic scoring systems. In many studies of different cohorts, it has been demonstrated that lower overall survival (OS) can be predicted by mutations in TP53, EZH2, ETV6, RUNX1, and ASXL1 in multivariable models adjusted for International Prognostic Scoring System (IPSS) or Revised International Prognostic Scoring System (IPSS-R) risk groups. [ 14 , 15 ] Decreased OS has also been linked to other altered genes, such as U2AF1, SRSF2, KRAS, SETBP1, DNMT3A, CBL, and PRPF8. [ 14–20 ] Even after adjusting for the IPSS-R, better results have been linked to only SF3B1 mutations in some, but not all studies. [ 15 , 21 , 22 ] The goal of our study was to determine the impact of using NGS in clinical practice on the overall survival of MDS patients.
medicine, general & internal